Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | GORTEC 2017-01 REACH: avelumab, cetuximab, and radiotherapy in LA-SCCHN

Makoto Tahara, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan, comment on the Phase III GORTEC 2017-01 REACH trial (NCT02999087), which compared avelumab, cetuximab with radiotherapy against standard-of-care (SOC) treatments in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). In cisplatin-unfit patients, the combination improved progression-free survival (PFS) and reduced distant metastasis rates but did not enhance overall survival (OS). This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.